Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
about
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study.Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.
P2860
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Tenofovir disoproxil fumarate ...... B: A 5-year randomised study.
@en
Tenofovir disoproxil fumarate
@nl
type
label
Tenofovir disoproxil fumarate ...... B: A 5-year randomised study.
@en
Tenofovir disoproxil fumarate
@nl
prefLabel
Tenofovir disoproxil fumarate ...... B: A 5-year randomised study.
@en
Tenofovir disoproxil fumarate
@nl
P2093
P1476
Tenofovir disoproxil fumarate ...... s B: A 5-year randomised study
@en
P2093
Andrzej Horban
Benedetta Massetto
Cihan Yurdaydin
Edward Gane
Florin A Caruntu
G Mani Subramanian
Hie-Won Hann
Ioan Sporea
John F Flaherty
John G McHutchison
P356
10.1016/J.JHEP.2016.08.008
P50
P577
2016-08-18T00:00:00Z